Magazine article from our research archive:

FDA announces new program for isotretinoin Rx: physicians required to comply by Dec. 31.

In a move that caught many in the medical community by surprise, the Food and Drug Administration last month announced a comprehensive--and mandatory--risk management program for the teratogenic acne drug isotretinoin and demands complete compliance by year's end.

The new program, called iPLEDGE, will require registration and ongoing compliance by all physicans and patients by Dec. 31, 2005. The iPLEDGE initiative replaces Roche's voluntary program for Accutane, called the System to Manage Accutane Related Teratogenicity (SMART), and similar programs for the four generic versions of isotretinoin.

The FDA informed physicians in November 2004 that SMART would be ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!